Octozi
Category: AI in Healthcare
Agentic AI platform that automates clinical trial data operations for pharmaceutical sponsors and CROs. Octozi was founded in 2023. The company is led by Amit Patel. Based in New York City, New York, USA. Team size: 1-10. Total funding raised: $3M. Latest round: Seed. Key investors include Surface Ventures (lead), Remarkable Ventures, Debiopharm Innovation Fund (pre-seed).
- Founded
- 2023
- Headquarters
- New York City, New York, USA
- Team size
- 1-10
- Total funding
- $3M
Value proposition
Octozi automates clinical trial data cleaning, review, reconciliation, and reporting using AI agents with human-in-the-loop oversight, reducing data cleaning time by 6x, cutting error rates from 54.7% to 8.5%, and saving an estimated $5M+ per Phase III trial.
Products and solutions
Octozi Clinical Intelligence Platform — five modules covering data cleaning, data review, reconciliation, reporting, and clinical operations, AI agents for Clinical Science, Safety, Data Management, Medical Monitoring, and Clinical Operations, continuous review engine that ingests data from EDC, Labs, CTMS, eCOA, and IRT systems.
Unique value
Purpose-built AI for clinical data operations (not a general-purpose dashboard); human-in-the-loop design ensuring regulatory compliance; proprietary LLMs fine-tuned from Llama 4 combined with deterministic clinical algorithms and external medical knowledge; proven 6x throughput improvement and 15x false-positive reduction in peer-reviewed study.
Target customer
Pharmaceutical sponsors (large pharma and biotech startups) and Contract Research Organizations (CROs) conducting clinical trials.
Industries served
Pharmaceutical / Biotech clinical development, oncology and broad therapeutic areas, Phase I-IV trials.
Technology advantage
Proprietary LLMs derived from Llama 4, fine-tuned specifically for clinical trial data cleaning; hybrid architecture combining LLMs with heuristic clinical algorithms; 100+ models per sponsor protocol; SOC 2 Type II, GDPR, FDA 21 CFR Part 11, GxP validated; zero-trust security; no training on customer data.
How they differentiate
Octozi focuses exclusively on the clinical data operations layer (cleaning, review, reconciliation, reporting) rather than drug discovery or trial design. Unlike dashboard-only tools, Octozi actively performs data work alongside human teams. Its human-in-the-loop design provides traceability and accountability required by regulators. Proven peer-reviewed results with 6x throughput improvement and $5M+ savings per Phase III trial.
Main competitors
BioPhy, Nyquist AI, Argon AI, Unlearn.AI (adjacent — digital twins for clinical trials), Perceptic (broader drug discovery-to-trial platform)
Key partnerships
Debiopharm Innovation Fund (strategic investor and partner, pre-seed), Surface Ventures (seed lead), Remarkable Ventures (seed participant).
Major milestones
Founded 2023, Published peer-reviewed study on AI-assisted clinical data cleaning (arXiv 2508.05519, Aug 2025), Joined Debiopharm Day One accelerator and presented at Roche HQ (Dec 2025), Debiopharm Innovation Fund pre-seed investment (Jun 2025), $3M seed round led by Surface Ventures (Jul 2026), SOC 2 Type II, FDA 21 CFR Part 11, GxP validated.
Market positioning
Early-stage disruptor in the clinical data operations segment of the $50B+ clinical development market. Differentiated by purpose-built agentic AI for data cleaning/review rather than general analytics dashboards. Backed by a unique Swiss pharma (Debiopharm) anchor before US VC involvement.
Geographic focus
US-headquartered (New York) with European pharma connections via Debiopharm partnership; targeting global pharmaceutical sponsors and CROs.
About Amit Patel
Ex-Google (Google X security project); Ex-Meta (Facebook); Ex-Tempo; Gaingels member. Stanford University (Economics degree).
Official website: https://www.octozi.com